Entering the mainstream of cancer treatment (original) (raw)

Decade in review—cancer immunotherapy

Nature Reviews Clinical Oncology volume 11, pages 630–632 (2014)Cite this article

Subjects

By November 2004, when the first issue of Nature Reviews Clinical Oncology was published, cancer immunotherapy had been successfully applied to the treatment of selected human cancers; however, dramatic progress in the following decade has moved immunotherapy from the sidelines of cancer treatment into the mainstream of modern oncology.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: Adoptive cell transfer immunotherapy.

References

  1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
    Article CAS Google Scholar
  2. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
    Article CAS Google Scholar
  3. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
    Article CAS Google Scholar
  4. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 422 (2010).
    Article Google Scholar
  5. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
    Article CAS Google Scholar
  6. Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798–808 (2012).
    Article Google Scholar
  7. Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2013).
    Article Google Scholar
  8. Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270 (2008).
    Article CAS Google Scholar
  9. Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).
    Article CAS Google Scholar
  10. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, 10 Center Drive MSC 1201, Bethesda, 20892, MD, USA
    Steven A. Rosenberg

Authors

  1. Steven A. Rosenberg
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toSteven A. Rosenberg.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

About this article

Cite this article

Rosenberg, S. Entering the mainstream of cancer treatment.Nat Rev Clin Oncol 11, 630–632 (2014). https://doi.org/10.1038/nrclinonc.2014.174

Download citation